The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2- Breast Cancer: A Multicenter Observational Study from Turkey.

Cancers (Basel) · 2025 · PMC12071266 · PMID 40361516

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

showed a trendp = 0.073so close (0.05 < p ≤ 0.1)

Bone metastasis showed a trend toward statistical significance (HR = 2.283, 95% CI: 0.927–5.624, p = 0.073).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.